Shares of Spherix Inc. soared on 6 March 2020 shortly after the company announced that it had executed an exclusive option agreement with the University of Maryland, Baltimore, for the technology claimed in a patent entitled "Methods of Treating Coronavirus Infection". The patent claims a method for treating coronavirus by administering a therapeutically effective amount of kinase signaling inhibitor selected from the group consisting of imatinib mesylate, nilotinib hydrochloride and dasatinib. It will be interesting to see if the method is effective for treating COVID-19.

Read more here.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.